Impact of glucocorticoid therapy on short- and long-term mortality in immunocompromised patients with community-acquired pneumonia in the ICU: a retrospective cohort study

Key Points

• Mortality rates increase among immunocompromised patients receiving glucocorticoids, raising safety concerns.
• Twenty-eight-day, six-month, and twelve-month mortality rates suggest significant risk tied to glucocorticoid use.
• Retrospective cohort analysis on immunocompromised patients with community-acquired pneumonia reveals critical findings.
• Further research is needed to determine the safest glucocorticoid treatment regimen for this vulnerable population.